Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.
Journal of the American College of Cardiology(2023)
Abstract
Treatment with goflikicept prevented recurrences and maintained IRP remission with a favorable risk-benefit ratio. Goflikicept reduced the risk of recurrence compared with placebo. (Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis; NCT04692766).
MoreTranslated text
Key words
autoinflammatory diseases,biologics,inflammation,interleukin-1 inhibitor
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined